EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma
Timothy D Clay, Prudence A Russell, Hongdo Do, Vijaya Sundararajan, Matthew Conron, Gavin M Wright, Benjamin Solomon, Alexander Dobrovic, Sue-Anne McLachlan, Melissa M Moore
Medical Oncology | HUMANA PRESS INC | Published : 2017
Funding for this study was provided by St. Vincent's Hospital research endowment fund. Dr Clay was supported by Australian Postgraduate Award from the University of Melbourne.